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excellent plan quality with similar MF and beam-on time. Jaw tracking is recommended for future clinical SBRT plan optimization. 
| INTRODUCTION
Recent advances in stereotactic body radiotherapy (SBRT) technology have greatly improved the ability to deliver conformal therapeutic tumor dose with a biological effective dose (BED) of greater than 100 Gy while minimizing the dose to the adjacent organs at risk (OAR). [1] [2] [3] Several studies have shown that safely delivering a higher BED to the lung lesions improved therapeutic ratio and local control rates. [4] [5] [6] [7] [8] [9] [10] In addition, utilizing volumetric modulated arc therapy (VMAT) planning with a flattening filter free (FFF) beam in lung SBRT treatment reduced the total number of monitor units (MUs) 11, 12 and the treatment time compared to intensity modulated radiotherapy, Tomotherapy, or CyberKnife. [13] [14] [15] [16] Reduction in MUs provides faster treatment delivery that can improve patient comfort, decrease potential setup/motion related errors and promote efficient clinical workflow. Owing to those advantages, VMAT SBRT planning using single isocenter for multiple targets has been gaining popularity in clinics for treating multiple intracranial tumors 17, 18 as well as extracranial oligometastases lesions. [19] [20] [21] [22] [23] Conversely, VMAT averages the dose delivery over more angles and produces slightly higher non-target low dose distribution compared to intensity modulated radiation therapy (IMRT). Generally, the treatment fields are designed with the jaw apparatus and tertiary multi-leaf collimators (MLCs) shaping the target volume. The jaw apparatus is fixed on the maximum field size of MLCs during treatment delivery, and thus leakage and transmission of radiation through the MLCs is present in the optimized IMRT/VMAT plan. This effect is noticeable while utilizing single-isocenter/multitarget VMAT plan. When the isocenter to tumor distance is large (on the order of 4-10 cm), the MLCs have to travel a longer distance to provide the target coverage to each lesion, potentially delivering higher non-trivial low-dose spillage to the non-target tissues such as normal lungs.
Due to the higher radiosensitivity, non-target normal tissue dose is one of the major concerns for SBRT treatments. [24] [25] [26] [27] However, if the jaws move to track MLC positions (called jaw tracking, JT technique on Truebeam), the radiation transmitted, and leakage dose to the normal tissues can be reduced.
Although the advantages of JT-IMRT/VMAT plans with flattened beams have been studied previously, [28] [29] [30] [31] [32] Alto, CA) algorithm on the 3D CT images with heterogeneity corrections using a 2.0 × 2.0 × 2.0 mm 3 dose calculation grid-size. Dose to medium was reported. All clinical plans were inversely optimized using variation of gantry rotation speed, dose rate, and MLC positions. In addition to optimization ring structures, the generalized normal tissue objective (NTO) parameters were used to control the gradients for each target. Planning objectives were per RTOG 0915
guidelines. These patients were treated every other day per lung SBRT protocol.
2.B.2 | Quality assurance and treatment delivery
For each plan, a verification plan was generated in the Eclipse TPS using an Octavius phantom (PTW, Freiburg, Germany). Doses re-calculated on the phantom's 2D ionization chamber array were exported and compared to a measured dose distribution. Using the γ-evaluation method of VeriSoft (Version 6.3, PTW) the two distributions were compared using the standard clinical gamma passing rate criteria of 3%/3 mm maximum dose difference and distance-toagreement with 10% threshold as well as maximum point dose. The
Octavius QA pass rates for the single-isocenter/two-lesion lung SBRT plan were 98.8 ± 2.5%, on average, for 3%/3 mm clinical gamma pass rate criteria and the maximum point dose measurement was 1.0 ± 0.7%, on average, suggesting that lung SBRT plans using JT can be accurately delivered. The beam-on time was estimated by using dose rates of 1400 MU/min for these plans. The dose-rate was confirmed by reviewing each VMAT arc for all patients under the MLC properties in Eclipse. Additionally, maximum dose rate of 1400 MU/min was visually observed during VMAT QA delivery at
Truebeam for all single-isocenter/two-lesion lung SBRT plans.
Before delivering each JT-VMAT SBRT treatment, a daily quality assurance check on kilovoltage to megavoltage imaging isocenter coincidence was performed, including IsoCalc measurement for precise and accurate target localization. Our IsoCalc localization accuracy for Truebeam was <0.5 mm. All the quality assurance procedures were in compliance for SBRT treatment delivery.
The patients received daily cone beam CT per image-guidance procedures established in our clinic.
2.B.3 | No JT-VMAT plan
The JT-VMAT SBRT treatment plans for all patients were retrospectively computed with a no JT-VMAT approach. All the planning objectives used in the no JT-VMAT were identical to the JT-VMAT plan including the NTO parameters and ring structures. The no JT-VMAT SBRT plan received the same target coverage as the JT-VMAT plan. Dosimetric parameters for the target coverage and the dose to adjacent OAR including normal lung doses were evaluated.
2.C | Plan evaluation
The dose volume histograms (DVHs) and isodose curves of JT-VMAT vs no JT-VMAT plans were compared. The Conformity index (CI), heterogeneity index (HI), gradient index (GI), gradient distance (GD), and D 2cm were calculated per RTOG 0915 recommendations. The dose to the normal lung was evaluated using V5, V10, V20, mean lung dose (MLD), and maximum dose to 1000 cc of lungs. Furthermore, dosimetric disparities were evaluated for spinal cord, heart, bronchial tree, esophagus, trachea, ribs, and skin following RTOG guidelines. The mean and standard deviation values for each of the dose metrics were compared using paired t tests for JT-VMAT vs no JT-VMAT using P < 0.05.
To estimate the normal lung dose as a function of target distance from the single isocenter, the isocenter to tumor distance was calculated as the maximum 3D-linear distance from the isocenter to the geometric center of each tumor. This distance was calculated in the Eclipse TPS using the x-, y-, and z-primary coordinates of the tumor centers. Moreover, the modulation factor (MF) as a function of isocenter to tumor distance was evaluated by using total number of monitor units (MUs) delivered for the both JT-VMAT and no-JT VMAT SBRT plans. The MF is defined as the total number of MUs divided by the prescription dose in cGy.
| RESULTS

3.A | Targets coverage
Both plans were normalized to receive the same target coverage (i.e., PTVD95 = 100%). Although jaw tracking was applied for JT-VMAT compared to no JT-VMAT plan, the dose distribution in the target volumes remained comparable with no significant differences in conformity and uniformity indices, as shown in Table 2 Table 2 ) compared to no JT-VMAT plan.
3.B | Dose to lungs
The absolute differences between single-isocenter JT-VMAT and no JT-VMAT SBRT plans for normal lung V20, V10, V5, MLD, and the maximum dose received by 1000 cc of lungs are listed in Table 3 .
All patients had V20 < 10%-15% for JT-VMAT treatment plans per protocol. The absolute differences of V20, V10, and V5 were up to 2%, 3%, and 4% higher, respectively with no JT-VMAT plans. Doses to all lung parameters increase uniformly with no JT-VMAT plan T Combined planning target volume (PTV) = PTV1 plus PTV2. CI = conformity index, total volume covered by the 100% isodose line divided by the volume of the combined PTV. HI, heterogeneity index = D10%/ D95%, where D10% is the dose to the hottest 10% of the combined PTV and D95% is the dose to the 95% of the combined PTV coverage. R50 (%) = ratio of 50% prescription isodose volume to the combined PTV. D2 cm (%) = maximum dose (in % of dose prescribed) 2 cm away from PTV in any direction. GI = R50%/R100%, R50% is the ratio of 50% prescription isodose volume to the combined PTV and R100% is the ratio of 100% prescription isodose volume to the combined PTV. GD (cm) = is the average distance from 100% prescription dose to 50% of the prescription dose. Statistically significant P-values are in bold, n.s. = not significant.
compared to JT-VMAT plan, giving statistically significant differences (P = 0.002, 0.003, 0.001, 0.001, and 0.001, respectively). Statistically significant P-values are in bold (see Table 3 ).
The variation of ratios between no JT-VMAT and JT-VMAT as a function of isocenter to tumor distance for V5, V10, V20, MLD, and maximum dose to 1000 cc of lungs including absolute differences is shown in Fig. 3 . For identical planning objectives and optimization parameters, V5, V10, V20, MLD, and maximum dose to 1000 cc of lungs were uniformly higher by 6% (range, 2%-16%), 8% (range, 2-29%), 8% (range, 2%-22%), 8% (range, 3%-25%), and 11% (range, 2%-19%), on average, respectively, compared to clinical JT-VMAT plan. In terms of absolute differences, V20, V10, V5, and MLD were higher by up to 1.9%, 6.5%, 6.5%, and 1.6 Gy (in some cases) with no JT-VMAT compared to JT-VMAT, respectively. This could be explained by the fact that MLC transmission contributed low-dose spillage in the normal lung due to MLC traveling longer distances (as a function of isocenter to tumor distance) to provide the same target coverage.
3.C | Dose to other OAR
A comparison of other OAR dosimetric parameters for single-isocenter/two-lesion JT-VMAT and no JT-VMAT plans for all 12 lung SBRT patients is presented in Table 4 No JT-VMAT minus JT-VMAT 0.7 ± 0.6 (0.2 to 1.9) 1.9 ± 1.7 (0.2 to 6.5) 2.3 ± 1.9 (0.6 to 6.5) 0.5 ± 0.4 (0.2 to 1.6) 0.7 ± 0.6 (0.3 to 2.1) P-value P = 0.002 P = 0.003 P = 0.001 P = 0.001 P = 0.001
Statistically significant P-values are in bold.
It was observed that the volumetric dose difference to heart, trachea, and skin were statistically significant (P-values, 0.01, 0.02, and 0.01, respectively) between the two plans. Overall, the doses with no JT-VMAT SBRT were higher by 1%-16% for the most of the critical organs, suggesting that the average values of absolute dose differences could be higher with no JT-VMAT plan of the order of 1-2 Gy compared to clinical JT-VMAT plan.
3.D | Modulation factor and beam-on time
The MF for no JT-VMAT vs JT-VMAT and the MF as a function of the isocenter to tumor distance is shown in Fig. 4 . For the given lung SBRT plan, the total number of MUs did not change significantly while using JT options for plan optimization, suggesting that the both plans gave similar MF. The average values of the MF for no JT-VMAT vs JT-VMAT were 3.72 ± 0.97 vs 3.75 ± 0.94, respectively. The average beam on time for JT-VMAT plan was 3.8 ± 1.7 min similar to that of no JT-VMAT plan (3.7 ± 1.1 min) thus not affecting the beam-on time, significantly.
However, MF increases as a function of isocenter to tumor distance (see right panel in Fig. 4 ), suggesting that farther apart the tumors, the more MUs are required to deliver the target coverage and consequently more low-dose spillage to the non-target tissues.
Scatter plot: Ratios of normal lungs V5, V10, V20, MLD, and maximum dose to 1000 cc of lungs calculated by volumetric modulated arc therapy with no jaw tracking (no JT-VMAT) and JT-VMAT plans as a function of isocenter to tumor distance. For the identical plan parameters and objectives, the no JT-VMAT plans gave higher V5, V10, V20, MLD and maximum dose to 1000 cc of lungs by 6%, 8%, 8%, 8%, and 11%, on average, respectively, compared to JT-VMAT plans. in this study were generally consistent with previous studies, [28] [29] [30] [31] [32] [33] [34] yet relatively higher differences (up to 11%) were observed, perhaps due to the unique complexity of the clinical situations and the distance between the tumors. It is worthwhile to mention that MLC transmission of our 6 MV-FFF beam was 1.2% and was modeled by the TPS and incorporated in the dose calculation.
One of the major concerns for treating multiple lung lesions synchronously using single-isocenter SBRT plan was the non-trivial low-dose spillage in the normal lung, such as V20, V10, V5, and MLD, as described above. Per RTOG recommendation, all of our single-isocenter/two-lesion JT-VMAT lung SBRT plans had V20 < 10%-15%. Moreover, for our JT-VMAT plans normal lung V5 and MLD were kept less than 40% and 6.0 Gy, on average, respectively. [25] [26] [27] It was observed that when the isocenter to tumor distance increased, the normal lung V20, V10, V5, MLD, and maximum dose to 1000 cc of normal lung increased. Our treatment planning strategy favored minimizing lung dose with the jaw tracking approach. By selecting patient specific collimator angles in conjunction with jaw tracking the MLC transmission and leakage dose due to the leaves traveling in between two tumors can be minimized. This can potentially help reduce severe lung toxicity with careful attention to normal lung dose parameters such as V5, V10, V20, and MLD during VMAT plan optimization and perhaps JT-VMAT plan may decrease the probability of developing radiation-induced acute or late side effects. 
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